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Background: While improving upon results achieved by balloon angioplasty (BA) alone for the treatment of femoropopliteal (FP) disease, stents 
have been prone to fractures and higher recurrence rates when placed in the more distal portion of this vascular segment. Furthermore, the 
presence of calcification is associated with dissection, vessel recoil and suboptimal results. This study examines whether the Diamondback 3600 
PAD System (DB), by improving lesion compliance through differential sanding, can achieve satisfactory acute and durable results without the need 
for stent placement. This abstract reports the acute results of this study.
Methods: This prospective, randomized, multicenter feasibility study enrolled 50 patients with de-novo, calcium-containing FP lesions of ≥70% 
producing Rutherford class 2 - 4 symptoms that were randomized equally to therapy with BA alone vs. DB followed by low pressure BA up to 4 
atmospheres (atm), if needed, with the angiographic endpoint of a residual stenosis ≤30%. Lesions failing to achieve this endpoint with the 
prescribed therapy were then treated with adjunctive (bailout) stenting. Baseline demographics, procedural and clinical parameters including 
Rutherford class and ankle-brachial-index (ABI) were recorded. The patients will have clinical followup at 1, 6 and 12 months along with duplex 
scanning and ABI determination. Freedom from target lesion revascularization including the need for bailout stenting and restenosis, defined as a 
peak systolic velocity ratio of ≥2.5 on duplex study at 6 months, is the primary endpoint.
Results: 82.4% of the lesions in the DB arm vs. 17.9% in the BA arm (p <0.0001) met the angiographic endpoint after primary therapy. Maximal 
balloon inflation pressure (a proxy for lesion compliance) was 3.8 atm in the DB arm vs. 8.9 atm in the BA arm (p <0.0001). There were 5 (14.7%) 
lesion dissections in the DB arm vs. 11 (39.3%) in the BA arm (p = 0.028). Just 2 (5.9%) lesions required stents in the DB arm vs. 22 (78.6%) in the 
BA arm (p <0.0001).
Conclusion: Compared to BA, DB leads to better luminal gain, improved lesion compliance, fewer dissections and a marked reduction in bailout 
stenting when treating calcium-containing FP disease.
